- Home
- MFA vs ARQT Comparison
MFA vs ARQT Comparison
Compare MFA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- ARQT
- Stock Information
- Founded
- MFA 1997
- ARQT 2016
- Country
- MFA United States
- ARQT United States
- Employees
- MFA N/A
- ARQT N/A
- Industry
- MFA Real Estate Investment Trusts
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- ARQT Health Care
- Exchange
- MFA Nasdaq
- ARQT Nasdaq
- Market Cap
- MFA 1.1B
- ARQT 1.1B
- IPO Year
- MFA N/A
- ARQT 2020
- Fundamental
- Price
- MFA $10.55
- ARQT $13.08
- Analyst Decision
- MFA Buy
- ARQT Strong Buy
- Analyst Count
- MFA 5
- ARQT 5
- Target Price
- MFA $13.50
- ARQT $17.00
- AVG Volume (30 Days)
- MFA 929.4K
- ARQT 1.9M
- Earning Date
- MFA 02-19-2025
- ARQT 02-25-2025
- Dividend Yield
- MFA 13.26%
- ARQT N/A
- EPS Growth
- MFA N/A
- ARQT N/A
- EPS
- MFA 1.60
- ARQT N/A
- Revenue
- MFA $366,192,000.00
- ARQT $138,708,000.00
- Revenue This Year
- MFA N/A
- ARQT $215.24
- Revenue Next Year
- MFA $14.93
- ARQT $53.63
- P/E Ratio
- MFA $6.60
- ARQT N/A
- Revenue Growth
- MFA 164.50
- ARQT 182.84
- 52 Week Low
- MFA $9.36
- ARQT $5.38
- 52 Week High
- MFA $13.45
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- MFA 56.59
- ARQT 41.94
- Support Level
- MFA $10.06
- ARQT $13.33
- Resistance Level
- MFA $10.57
- ARQT $15.09
- Average True Range (ATR)
- MFA 0.19
- ARQT 0.86
- MACD
- MFA 0.08
- ARQT -0.16
- Stochastic Oscillator
- MFA 92.91
- ARQT 6.25
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company is an internally managed real estate investment trust or REIT.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.